Cargando…

Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials

BACKGROUND: Effective antiplatelet therapy is critical for patients with ST-segment elevation myocardial infarction (STEMI) and receiving primary percutaneous coronary interventions (PPCI). Intracoronary (IC) and intravenous (IV) administration of tirofiban are commonly used during the procedure of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Rui, Liu, Rugang, Zhang, Jiajun, Li, Yong, Wei, Shujian, Xu, Feng, Li, Xiaoxing, Li, Chuanbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172923/
https://www.ncbi.nlm.nih.gov/pubmed/37180928
http://dx.doi.org/10.1016/j.heliyon.2023.e15842
_version_ 1785039718570786816
author Tian, Rui
Liu, Rugang
Zhang, Jiajun
Li, Yong
Wei, Shujian
Xu, Feng
Li, Xiaoxing
Li, Chuanbao
author_facet Tian, Rui
Liu, Rugang
Zhang, Jiajun
Li, Yong
Wei, Shujian
Xu, Feng
Li, Xiaoxing
Li, Chuanbao
author_sort Tian, Rui
collection PubMed
description BACKGROUND: Effective antiplatelet therapy is critical for patients with ST-segment elevation myocardial infarction (STEMI) and receiving primary percutaneous coronary interventions (PPCI). Intracoronary (IC) and intravenous (IV) administration of tirofiban are commonly used during the procedure of PPCI. However, which is the better administration route of tirofiban have not been fully evaluated. METHODS: A comprehensive literature search of RCTs that comparing IC with IV tirofiban in STEMI patients undergoing PPCI was conducted, which were published as of May 7, 2022, in PubMed, Embase, Cochrane Library, Web of Science, Scopus and ClinicalTrials.gov. The primary efficacy endpoint was 30-day major adverse cardiovascular events (MACE) and the primary safety endpoint was in-hospital bleeding events. RESULTS: This meta-analysis included 9 trials involving 1177 patients. IC tirofiban significantly reduced the incidence of 30-day MACE (RR 0.65, 95% CI: 0.44 to 0.95, P = 0.028) and improved the rate of the thrombolysis in myocardial infarction (TIMI) grade 3 flow in high-dose (25 μg/kg) group (RR = 1.13, 95% CI: 0.99–1.30, P = 0.001), in-hospital (WMD 2.03, 95% CI: 1.03 to 3.02, P < 0.001), and 6-month left ventricular injection fraction (LVEF) (WMD 6.01, 95% CI: 5.02 to 6.99, P < 0.001) compared with IV. There was no significant difference in the incidences of in-hospital bleeding events (RR 0.96, 95% CI: 0.67 to 1.38, P = 0.82) and thrombocytopenia (RR 0.63, 95% CI: 0.26 to 1.57, P = 0.32) between the two groups. CONCLUSIONS: IC tirofiban significantly improved the incidence of TIMI 3 in the high-dose group, in-hospital and 6-month LVEF, and reduced the 30-day MACE incidence without increasing the risk of bleeding compared with IV.
format Online
Article
Text
id pubmed-10172923
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101729232023-05-12 Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials Tian, Rui Liu, Rugang Zhang, Jiajun Li, Yong Wei, Shujian Xu, Feng Li, Xiaoxing Li, Chuanbao Heliyon Research Article BACKGROUND: Effective antiplatelet therapy is critical for patients with ST-segment elevation myocardial infarction (STEMI) and receiving primary percutaneous coronary interventions (PPCI). Intracoronary (IC) and intravenous (IV) administration of tirofiban are commonly used during the procedure of PPCI. However, which is the better administration route of tirofiban have not been fully evaluated. METHODS: A comprehensive literature search of RCTs that comparing IC with IV tirofiban in STEMI patients undergoing PPCI was conducted, which were published as of May 7, 2022, in PubMed, Embase, Cochrane Library, Web of Science, Scopus and ClinicalTrials.gov. The primary efficacy endpoint was 30-day major adverse cardiovascular events (MACE) and the primary safety endpoint was in-hospital bleeding events. RESULTS: This meta-analysis included 9 trials involving 1177 patients. IC tirofiban significantly reduced the incidence of 30-day MACE (RR 0.65, 95% CI: 0.44 to 0.95, P = 0.028) and improved the rate of the thrombolysis in myocardial infarction (TIMI) grade 3 flow in high-dose (25 μg/kg) group (RR = 1.13, 95% CI: 0.99–1.30, P = 0.001), in-hospital (WMD 2.03, 95% CI: 1.03 to 3.02, P < 0.001), and 6-month left ventricular injection fraction (LVEF) (WMD 6.01, 95% CI: 5.02 to 6.99, P < 0.001) compared with IV. There was no significant difference in the incidences of in-hospital bleeding events (RR 0.96, 95% CI: 0.67 to 1.38, P = 0.82) and thrombocytopenia (RR 0.63, 95% CI: 0.26 to 1.57, P = 0.32) between the two groups. CONCLUSIONS: IC tirofiban significantly improved the incidence of TIMI 3 in the high-dose group, in-hospital and 6-month LVEF, and reduced the 30-day MACE incidence without increasing the risk of bleeding compared with IV. Elsevier 2023-04-28 /pmc/articles/PMC10172923/ /pubmed/37180928 http://dx.doi.org/10.1016/j.heliyon.2023.e15842 Text en © 2023 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Tian, Rui
Liu, Rugang
Zhang, Jiajun
Li, Yong
Wei, Shujian
Xu, Feng
Li, Xiaoxing
Li, Chuanbao
Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials
title Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials
title_full Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials
title_fullStr Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials
title_full_unstemmed Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials
title_short Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials
title_sort efficacy and safety of intracoronary versus intravenous tirofiban in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172923/
https://www.ncbi.nlm.nih.gov/pubmed/37180928
http://dx.doi.org/10.1016/j.heliyon.2023.e15842
work_keys_str_mv AT tianrui efficacyandsafetyofintracoronaryversusintravenoustirofibaninpatientswithstsegmentelevationmyocardialinfarctionundergoingprimarypercutaneouscoronaryinterventionametaanalysisofrandomizedcontrolledtrials
AT liurugang efficacyandsafetyofintracoronaryversusintravenoustirofibaninpatientswithstsegmentelevationmyocardialinfarctionundergoingprimarypercutaneouscoronaryinterventionametaanalysisofrandomizedcontrolledtrials
AT zhangjiajun efficacyandsafetyofintracoronaryversusintravenoustirofibaninpatientswithstsegmentelevationmyocardialinfarctionundergoingprimarypercutaneouscoronaryinterventionametaanalysisofrandomizedcontrolledtrials
AT liyong efficacyandsafetyofintracoronaryversusintravenoustirofibaninpatientswithstsegmentelevationmyocardialinfarctionundergoingprimarypercutaneouscoronaryinterventionametaanalysisofrandomizedcontrolledtrials
AT weishujian efficacyandsafetyofintracoronaryversusintravenoustirofibaninpatientswithstsegmentelevationmyocardialinfarctionundergoingprimarypercutaneouscoronaryinterventionametaanalysisofrandomizedcontrolledtrials
AT xufeng efficacyandsafetyofintracoronaryversusintravenoustirofibaninpatientswithstsegmentelevationmyocardialinfarctionundergoingprimarypercutaneouscoronaryinterventionametaanalysisofrandomizedcontrolledtrials
AT lixiaoxing efficacyandsafetyofintracoronaryversusintravenoustirofibaninpatientswithstsegmentelevationmyocardialinfarctionundergoingprimarypercutaneouscoronaryinterventionametaanalysisofrandomizedcontrolledtrials
AT lichuanbao efficacyandsafetyofintracoronaryversusintravenoustirofibaninpatientswithstsegmentelevationmyocardialinfarctionundergoingprimarypercutaneouscoronaryinterventionametaanalysisofrandomizedcontrolledtrials